Navigation Links
PDL BioPharma Announces First Quarter 2009 Financial Results
Date:5/7/2009

March 17, 2009. The conversion rate for the 2023 Notes was previously 114.153 shares of common stock per $1,000 principal amount of the 2023 Notes. -- As a result of the April 1, 2009 dividend payment, we announced an adjustment to the conversion rate for the Company's 2.00% Convertible Senior Notes due February 15, 2012 (the "2012 Notes"). The conversion rate, as adjusted, is 89.165 shares of common stock per $1,000 principal amount of the 2012 Notes, effective March 17, 2009. The conversion rate for the 2012 Notes was previously 82.162 shares of common stock per $1,000 principal amount of the 2012 Notes. -- Alexion agreed to pay PDL $25 million, of which it paid $12.5 million in January 2009 and is obligated to pay the second installment of $12.5 million in June 2009. -- In February of 2009, we received a letter from MedImmune asserting that it may be entitled to pay a lower royalty rate on sales of Synagis because of our settlement with Alexion. In April of 2009, we sent a letter notifying MedImmune of the exercise of certain of our rights under our license agreement, the exercise of which we believe precludes MedImmune from being entitled to a lower royalty rate based on the Alexion settlement. -- Approval for Raptiva(R) was suspended in the European Union and in Canada in February of 2009 and product was withdrawn from the U.S. market in April of 2009 because of safety concerns. In 2008, royalties attributable to sales of Raptiva were $3.9 million or 1.3% of total revenue from continuing operations.

2009 Financial Guidance

PDL reaffirms its previous revenue guidance and continues to anticipate strong revenue growth in 2009 increasing from 2008 to a range of $310 to $325 million despite the recent withdrawal of Raptiva. Royal
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Sinobiopharma Secures Rights to Seven Key Patents
2. China Biologic Products Receives $5.3 Million Order from Largest Biopharmaceutical Distributor in India
3. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
4. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
5. Helix BioPharma to Present at the BioFinance 2009 Conference
6. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
7. 2009 Prix Galien USA Now Accepting Nominations for Top Prize in Biopharmaceutical Research and Development
8. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
9. Advanced Instruments Introduces 2020-BIO Multi-Sample Osmometer as First True Automation-Friendly Osmometer for the Biopharmaceutical Industry
10. XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
11. Sinobiopharma, Inc. Appoints New Director of Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... -- Research and Markets ( ... "Biotechnology for the Non-Biotechnologist" conference to ... ideal for non-Scientists and Scientists needing to understand ... biotechnology. Ideal for Non-Scientists and Scientists ... and potential of biotechnology Why you ...
(Date:7/6/2015)... , July 6, 2015 ImmunoCellular Therapeutics, Ltd. ... an agreement with Novella Clinical (Novella), to ... patients with newly diagnosed glioblastoma. Novella is a full-service, ... to small to mid-sized oncology companies. The ICT-107 phase ... the US, Europe and ...
(Date:7/3/2015)... WIEN , July 3, ... Tiedemiehet voivat hakea verkossa osoitteessa  ... for Open Innovation in Science" ... Ludwig Boltzmann Gesellschaftin (LBG) tekemän, ... tutkimuksen mukaan terveystieteiden kaksi suurinta ...
(Date:7/3/2015)... 3, 2015 Forskare ... 2015 på  http://www.openinnovationinscience.at till det återkommande ... som hålls i Wien ... med internationella forskare och vetenskapsmän som genomfördes ... två största utmaningar bristen på incitament för ...
Breaking Biology Technology:ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3
... 2011 Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced that ... the filing of the Marketing Authorization Application (MAA) for ... the treatment and prevention of bleeding in individuals with ... that it will begin its regulatory review process of ...
... Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO ) announced ... Jim Holmes, Lifeline,s CEO said "While our efforts ... have not been successful.  We now are considering alternatives should ... Lifeline is not reflected in the current lack of liquidity ...
... have developed polymers that fluoresce in the presence of bacteria, ... wound infection using ultra-violet light. When contained ... of fluorescence detected will alert clinicians to the severity of ... which bind to either gram negative or gram positive bacteria ...
Cached Biology Technology:Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B 2Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B 3Lifeline Biotechnologies and Depository Trust Company 2Sheffield scientists shine a light on the detection of bacterial infection 2
(Date:6/26/2015)... June 26, 2015 ATL Technology, LLC, a top ... specialties in single use solutions, headquartered in Springville, ... (a California corporation with locations in ... San Jose, Costa Rica ). This acquisition ... with ATL Technology,s existing facility in ...
(Date:6/25/2015)... PRINCETON, N.J. , June 25, 2015  TAKE ... awarded a patent by the United States Patent and ... Data Standardization". This process leverages TAKE Solutions, Clinical Accelerators ... by over 50% (when compared to standardization without the ... At the heart ...
(Date:6/24/2015)... SAN JOSE, Calif. , June 24, 2015 ... leading developer of human interface solutions, today announced ... fingerprint sensor to provide secure authentication for its ... Having recently reached more than 200 million shipments ... shipment with Sharp reinforces Synaptics, strength, scalability and ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2TAKE Solutions Awarded Patent By USPTO 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... new study shows that high school athletes playing at higher ... phenomenon attributed to physiological changes in the brain causing it ... the first time any research has linked altitude to sports-related ... the Colorado School of Public Health and co-author of the ...
... Study of the Liver (EASL) today publishes their revised ... C virus infection (HCV) (1). The EASL guidelines, ... designed to help physicians and other healthcare providers optimise ... It is estimated that approximately 160 million individuals, ...
... the development of tumours in over one per cent of ... gene CUX1 has been broadly linked to cancer development. ... pathway is activated that increases tumour growth. Drugs that inhibit ... and are in development thus highlighting a potential new targeted ...
Cached Biology News:Study shows first link between altitude and concussion 2EASL publishes revised clinical practice guidelines to optimise the management of hepatitis C virus 2EASL publishes revised clinical practice guidelines to optimise the management of hepatitis C virus 3Gene promotes 1 in 100 of tumors 2
Human Aminopeptidase P2/XPNPEP2 Affinity Purified PAb ENTREZ GeneID: 7512...
Collected from 8-12 week old sexually mature rats. Pricing: $100/unit for 1 - 10 units...
PlusOne Acrylamide PAGE, 1 kg. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Gel Casting Chemicals....
... RNA Quantitation Kit is one of ... the quantitation of RNA in solution. ... more sensitive than absorbance measurements. As ... detected with fluorescence microplate readers and ...
Biology Products: